Register
Login:
Share:
Email Facebook Twitter


RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum


Glaxosmithkline Share Price (GSK)



Share Price Information for Glaxosmithkline (GSK)


Share Price: 1,287.50Bid: 1,287.00Ask: 1,287.50Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.50Spread as %: 0.04%Open: 1,278.50High: 1,291.00Low: 1,273.00Yesterday’s Close: 1,287.50

Glaxosmithkline Plc Ord 25P

Glaxosmithkline is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Glaxosmithkline is part of the Medicine and Biotech Research sector

Glaxosmithkline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.





Share Price SpacerPrice
1287.50

Share Price SpacerBid
1287.00

Share Price SpacerAsk
1287.50

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
8,179,062

Share Price SpacerOpen
1,278.50

Share Price SpacerHigh
1,291.00

Share Price SpacerLow
1,273.00

Share Price SpacerClose
1,287.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 4,917.43m £63,311.94m 1,500

52 Week High 1,724.50 52 Week High Date 22-JUN-2017
52 Week Low 1,270.00 52 Week Low Date 6-DEC-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
9,915 3,065,108 4,482,293 68.484 18.80 80.00 6.21


London South East Users info for Glaxosmithkline


Users who watch GSK also watch: BP, Lloyds, Vodafone, Tesco, Barclays, RBS, HSBC, BT, National Grid, Astrazeneca

Users who hold GSK also hold: Vodafone, BP, Lloyds, National Grid, Royal Dutch Shell B, Tesco, HSBC, Aviva, BT, Centrica


Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

08-Dec-17
17:08:00
1,283.25
25,470
Sell* 
1,287.00
1,287.50
326.84k
Trade Type:
Ordinary
NonProtected portfolio
Single protected transaction

08-Dec-17
17:08:00
1,283.25
25,470
Sell* 
1,287.00
1,287.50
326.84k
Trade Type:
Ordinary
Delayed publication

08-Dec-17
17:08:23
1,280.25
51,816
Sell* 
1,287.00
1,287.50
663.37k
Trade Type:
Ordinary
Delayed publication




View more Glaxosmithkline trades >>

Directors Deals for Glaxosmithkline (GSK)
Trade DateActionNotifierPriceCurrencyAmountHolding
01-Dec-17Exercise of option
Trade Notifier Information for GlaxoSmithKline
Simon Dingemans held the position of CFO at GlaxoSmithKline at the time of this trade.
 Simon Dingemans
1131GBX23817564623
09-Nov-17Buy
Trade Notifier Information for GlaxoSmithKline
Emma Walmsley held the position of CEO at GlaxoSmithKline at the time of this trade.
 Emma Walmsley
1364.18GBX1085883
09-Nov-17Buy
Trade Notifier Information for GlaxoSmithKline
Simon Dingemans held the position of CFO at GlaxoSmithKline at the time of this trade.
 Simon Dingemans
1364.18GBX917564376
View more Glaxosmithkline directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Sun 23:54bob6TLWilliams.1,287.50No Opinion
very interesting post .well let's see what happens , you never know there may be some good news that gsk could do with this week.
Sun 12:21TLWilliams.RE: QUOTE JEFFERIES1,287.50Buy
A number of investors are in a similar position Bob. No one was anticipating the recent severe pruning (by the marke) to the share price. We would have all sold on Q3 day if this were the case, and bought back five weeks later. Regarding the dividend, it is assured for 2018. The CEO wouldn't contemplate otherwise, as she has most probably understood by now that her unconfident performance (especially regarding the dividend!) during the Q3 results announcement has had a very serious impact on… Read More
Sun 11:31JKG53New drugs1,287.50No Opinion
Sat 23:56bob6QUOTE JEFFERIES1,287.50No Opinion
Management has undermined confidence in the dividend,’ ‘Investors fear it could be sacrificed to acquire Pfizer’s consumer business. We think the dividend is too important to too many GSK shareholders for management to pursue this strategy.’

me, bob i totally agree

if you cut the dividend EMMA i suggest there should be a vote of no confidence in you, just look what damage
you have done so far sp,approx, £17 6 months ago now £12.875 so us… Read More
Sat 22:07FarmertallyBottom of the cycle1,287.50No Opinion
Added more this week - the chick cant do any worse then Witty and Woodys failures are spectacular : PFG, ALML, AA, NXT, AZN, IMB - the geezer is a nightmare - break up the company for better growth - what a teat -

£15 before i think of flogging a few.
Fri 20:07PokerchumpRE: GSK share price.1,287.50No Opinion
You in here as well I see, TL. Looks like we’re both having a tough time at the moment. You’re not in BT as well are you ? I’m on a hat-trick of poorly judged shares !! I assume you’re not going to try and trade yourself out of the loss, but just sit tight and wait for the upturn in fortunes ? Onwards and upwards.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Glaxosmithkline (GSK) >>

Please login or register to post a message on Share Chat.





Glaxosmithkline Plc Ord 25P home pageWebsite: Glaxosmithkline Plc Ord 25P
Website Description: GlaxoSmithKline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 99,300 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries. As of August 2016 it had a market capitalisation of £81 billion the fourth largest on the London Stock Exchange



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.